Hims & Hers Health, Inc. Investors Have Class Action Opportunity Before Deadline

Hims & Hers Health, Inc. Class Action Alert

In a significant announcement from Robbins Geller Rudman & Dowd LLP, investors in Hims & Hers Health, Inc. (NYSE: HIMS) who experienced substantial losses between August 4, 2025, and July 29, 2026, have the opportunity to step forward as lead plaintiffs in a pending class action lawsuit. The deadline to act is November 2, 2026. This lawsuit, which has been filed under the heading Velanki v. Hims & Hers Health, Inc., alleges serious violations of securities regulations by the company and some of its top executives.

The Allegations Against Hims & Hers

According to the allegations, Hims & Hers has been accused of misleading investors by failing to disclose crucial information regarding the handling of consumer health data and its billing practices. Key points from the complaint highlight that:
1. Data Sharing: Hims & Hers allegedly shared sensitive health information of consumers with third-party advertising firms without appropriate disclosure. This contradicts their claims of maintaining consumer privacy.
2. Billing Practices: The company purportedly charged customers for medications shortly after submission of their intake forms, misleading them about the process of consultation with medical providers. This has raised suspicions and led to regulatory scrutiny.
3. Regulatory Scrutiny: The lawsuit coincides with the Federal Trade Commission (FTC)'s announcement regarding its filing against Hims & Hers. The FTC has asserted that the company engaged in deceptive practices and false advertising, contributing to the significant drop in its stock price, which fell nearly 15% following the news.

The Legal Process for Class Action

The Private Securities Litigation Reform Act of 1995 provides a framework for investors to claim the status of lead plaintiff in such lawsuits. The lead plaintiff is generally the investor with the most substantial financial interest in the case and acts on behalf of all other affected shareholders. If chosen, the lead plaintiff can select legal counsel to represent the class in further proceedings.

Next Steps for Affected Investors

Affected investors are encouraged to reach out if they wish to learn more about participating as lead plaintiffs in this class action. Legal representatives from Robbins Geller Rudman & Dowd are available to assist potential plaintiffs with the necessary steps to file their claims. Interested individuals can contact the firm directly for more information.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller Rudman & Dowd LLP is a leading law firm renowned for its work in securities fraud and shareholder litigation. With a sterling reputation and a proven track record, including over $916 million recovered for investors in 2025 alone, they remain a prominent advocate for shareholders seeking justice.

For further inquiries or more information regarding this class action lawsuit, investors can reach Robbins Geller at 800-851-7783 or visit their official website.

As this case unfolds, all interested parties will have to monitor developments closely, especially as they pertain to investor rights and corporate responsibility within the health and wellness industry.